Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) EBT (2016 - 2025)

Historic EBT for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $57000.0.

  • International Stem Cell's EBT rose 14560.0% to $57000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$58000.0, marking a year-over-year increase of 9150.81%. This contributed to the annual value of -$213000.0 for FY2024, which is 7344.14% up from last year.
  • As of Q3 2025, International Stem Cell's EBT stood at $57000.0, which was up 14560.0% from $129000.0 recorded in Q2 2025.
  • International Stem Cell's EBT's 5-year high stood at $129000.0 during Q2 2025, with a 5-year trough of -$641000.0 in Q3 2021.
  • For the 5-year period, International Stem Cell's EBT averaged around -$181684.2, with its median value being -$131000.0 (2023).
  • As far as peak fluctuations go, International Stem Cell's EBT crashed by 885000.0% in 2023, and later soared by 16368.72% in 2024.
  • Over the past 5 years, International Stem Cell's EBT (Quarter) stood at -$364000.0 in 2021, then surged by 107.69% to $28000.0 in 2022, then crashed by 1735.71% to -$458000.0 in 2023, then soared by 102.62% to $12000.0 in 2024, then skyrocketed by 375.0% to $57000.0 in 2025.
  • Its last three reported values are $57000.0 in Q3 2025, $129000.0 for Q2 2025, and -$256000.0 during Q1 2025.